Pfizer launches free Sutent program in Nepal
Global drug behemoth Pfizer is reported to be launching a free drug access program for its oncology product Sutent (sunitinib malate) in Nepal. The move is seen as influential in the court case brought by Indian generic drugmaker Natco Pharma, which aims to allow the production of a copycat version of the patented agent.
The trial involves an attempt by the Hyderabad-based firm to invoke part of the World Trade Organization's agreement on Trade-Related Intellectual Property Rights (TRIPs), relating to the suspension of a patent in one country in order to supply a low-cost version of a medicine to another country that does not have the infrastructure to produce it locally.
Natco is also involved in another court case, this time with Switzerland's drug major Novartis, over the latter's cancer drug Tarceva (erlotinib; Marketletter March 24).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze